Literature DB >> 22569681

Are there high-risk subgroups for isolated locoregional failure in patients who had T1/2 breast cancer with one to three positive lymph nodes and received mastectomy without radiotherapy?

Yasushi Hamamoto1, Shozo Ohsumi, Kenjiro Aogi, Syuichi Shinohara, Naomi Nakajima, Masaaki Kataoka, Shigemitsu Takashima.   

Abstract

BACKGROUND: To define the factors associated with increased risk of isolated locoregional failure that may justify postmastectomy radiotherapy in patients with T1/2 breast cancer and 1-3 positive lymph nodes.
METHODS: Between 1990 and 2002, 248 patients who had pT1-2 breast cancer and 1-3 positive lymph nodes were treated with mastectomy without radiotherapy (age 32-84, median 54).
RESULTS: Median follow-up time was 82 months (range 2-189 months). For all patients, the 8-year isolated locoregional failure-free rate was 95 %. In univariate analysis, hormone receptor status and administration of hormone therapy were statistically significant factors, and vascular invasion was the borderline significant factor for isolated locoregional failure-free rates (P = 0.0377, 0.0181, and 0.0555, respectively). The 8-year isolated locoregional failure-free rates were 98 % for patients with positive hormone receptor status and 90 % for patients with negative hormone receptor status, 97 % for patients who received hormone therapy and 89 % for patients who did not receive hormone therapy, 92 % for patients with vascular invasion and 97 % for patients without vascular invasion. In multivariate analysis for hormone receptor status and vascular invasion, the former was statistically significant (P = 0.0491) and the latter was borderline significant (P = 0.0664). When patients had both negative hormone receptor and positive vascular invasion status, the 8-year isolated locoregional failure-free rates decreased to 83 %.
CONCLUSIONS: With regard to patients who had pT1/2 breast cancer and 1-3 positive lymph nodes, isolated locoregional failure was not common in general; however, patients who had both negative hormone receptor status and vascular invasion were comparatively high-risk patients for isolated locoregional failure.

Entities:  

Mesh:

Year:  2012        PMID: 22569681     DOI: 10.1007/s12282-012-0369-7

Source DB:  PubMed          Journal:  Breast Cancer        ISSN: 1340-6868            Impact factor:   4.239


  9 in total

1.  Most Breast Cancer Patients with T1-2 Tumors and One to Three Positive Lymph Nodes Do Not Need Postmastectomy Radiotherapy.

Authors:  Shirin Muhsen; Tracy-Ann Moo; Sujata Patil; Michelle Stempel; Simon Powell; Monica Morrow; Mahmoud El-Tamer
Journal:  Ann Surg Oncol       Date:  2018-03-21       Impact factor: 5.344

2.  Postmastectomy radiotherapy improves disease-free survival of high risk of locoregional recurrence breast cancer patients with T1-2 and 1 to 3 positive nodes.

Authors:  Zhen-Yu He; San-Gang Wu; Juan Zhou; Fang-Yan Li; Qin Lin; Huan-Xin Lin; Jia-Yuan Sun
Journal:  PLoS One       Date:  2015-03-17       Impact factor: 3.240

3.  Postmastectomy Radiotherapy: An American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Focused Guideline Update.

Authors:  Abram Recht; Elizabeth A Comen; Richard E Fine; Gini F Fleming; Patricia H Hardenbergh; Alice Y Ho; Clifford A Hudis; E Shelley Hwang; Jeffrey J Kirshner; Monica Morrow; Kilian E Salerno; George W Sledge; Lawrence J Solin; Patricia A Spears; Timothy J Whelan; Mark R Somerfield; Stephen B Edge
Journal:  Ann Surg Oncol       Date:  2016-09-19       Impact factor: 5.344

4.  Impact of postmastectomy radiation therapy in T1-2 breast cancer patients with 1-3 positive axillary lymph nodes.

Authors:  Hang Yin; Yuanyuan Qu; Xiaoyuan Wang; Tengchuang Ma; Haiyang Zhang; Yu Zhang; Yang Li; Siliang Zhang; Hongyu Ma; Enkang Xing; Xueying Liu; Qingyong Xu
Journal:  Oncotarget       Date:  2017-07-25

5.  Locoregional recurrence-associated factors and risk-adapted postmastectomy radiotherapy for breast cancer staged in cT1-2N0-1 after neoadjuvant chemotherapy.

Authors:  Xin Wang; Liming Xu; Zhenzhen Yin; Daquan Wang; Qi Wang; Kunpeng Xu; Jinlin Zhao; Lujun Zhao; Zhiyong Yuan; Ping Wang
Journal:  Cancer Manag Res       Date:  2018-10-02       Impact factor: 3.989

6.  Quantifying the number of lymph nodes for examination in breast cancer.

Authors:  Liping Sun; Ping Li; He Ren; Gang Liu; Lining Sun
Journal:  J Int Med Res       Date:  2019-10-23       Impact factor: 1.671

7.  The effects of ECE on the benefits of PMRT for breast cancer patients with positive axillary nodes.

Authors:  Wenwen Geng; Bin Zhang; Danhua Li; Xinrui Liang; Xunchen Cao
Journal:  J Radiat Res       Date:  2013-02-07       Impact factor: 2.724

8.  Effects of postmastectomy radiotherapy on prognosis in different tumor stages of breast cancer patients with positive axillary lymph nodes.

Authors:  Miao-Miao Jia; Zhi-Jie Liang; Qin Chen; Ying Zheng; Ling-Mei Li; Xu-Chen Cao
Journal:  Cancer Biol Med       Date:  2014-06       Impact factor: 4.248

9.  Predictive Value of Molecular Subtyping for Locoregional Recurrence in Early-Stage Breast Cancer with N1 without Postmastectomy Radiotherapy.

Authors:  Ge Wen; Jin-Shan Zhang; Yu-Jing Zhang; Yu-Jia Zhu; Xiao-Bo Huang; Xun-Xing Guan
Journal:  J Breast Cancer       Date:  2016-06-24       Impact factor: 3.588

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.